Cross-Sector entity
gene-therapy is the sole category represented across all 1 tracked stories. AMT-130 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Cross-Sector story that mention Jack Kaye, all published on August 5, 2026.
1 verified story tracked
Last mentioned: Aug 5, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
gene-therapy is the sole category represented across all 1 tracked stories. AMT-130 is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Cross-Sector story that mention Jack Kaye, all published on August 5, 2026. Each carries 3 original sources on average.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Jack Kaye. Shared-story counts are live from our verified record — not editorial picks.
SEC filings and market close
Stock closes at $27.57, up 2.8%; SEC Form 4 filings reveal the three insider transactions.
Insider sales executed
Directors Kaye, Balachandran, and Meek each sell 1,993 shares at $27.06.
Q1 2026 earnings
uniQure reports revenue of $3.56M (miss) and EPS of -$0.85 (beat by $0.03); net margin remains deeply negative.
RBC upgrade
RBC Capital upgrades uniQure from sector perform to outperform, raising price target from $11 to $35.
Three uniQure directors each offloaded 1,993 shares at $27.06, pocketing a combined $162K. The gene therapy company’s stock trades above key moving averages after an RBC upgrade, but sales hint at insider caution amid heavy cash burn.
Source: dailypolitical.com · themarketsdaily.com
